Subscribe To

Price Alert Latest News Economic Calendar News

ACET / Adicet Bio to Present at Upcoming Investor Conferences

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in September. Details of the events are as follows: H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022, New York, New York An on-d Read More

Demo Live Account See Partner Details

Content Topics

Adicet

Present

Upcoming

Investor

Conferences

Stock

ACET

Posted: Sep 7 2022, 16:10

Author Name: Business Wire

ACET News

By Zacks Investment Research
August 9, 2023

Adicet Bio, Inc. (ACET) Reports Q2 Loss, Lags Revenue Estimates

Adicet Bio, Inc. (ACET) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to los

By Zacks Investment Research
May 9, 2023

Adicet Bio, Inc. (ACET) Reports Q1 Loss, Misses Revenue Estimates

Adicet Bio, Inc. (ACET) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to ear

By Seeking Alpha
February 7, 2023

Adicet Bio: Searching For Upside In Cell Therapeutics

Biotechs developing CAR-T cell therapies have seen their valuations plummet in 2022 - making them an intriguing speculative buy opportunity in 2023. T

By Zacks Investment Research
January 25, 2023

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?

Here is how Adicet Bio, Inc. (ACET) and AlloVir, Inc. (ALVR) have performed compared to their sector so far this year.

By Zacks Investment Research
December 30, 2022

Down -53.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Adicet Bio, Inc. (ACET)

Adicet Bio, Inc. (ACET) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined wit

By Zacks Investment Research
December 14, 2022

Adicet Bio, Inc. (ACET) Loses 47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Adicet Bio, Inc. (ACET) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement

By Pulse2
December 12, 2022

Why The Adicet Bio (ACET) Stock Plummeted Over 35%

The stock price of Adicet Bio (ACET) plummeted over 35% intraday today. This is why.

By Market Watch
December 12, 2022

Adicet Bio shares fall as it shares clinical data about its CAR-T treatment candidate

Adicet Bio's Inc. ACET, -13.13% stock tumbled about 38% in premarket trading on Monday after the company shared data from a Phase 1 clinical trial eva

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.